NCT07318129
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
Recruiting · Not Applicable · Glostrup University Hospital, Copenhagen · registry updated 2026-01-28
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
Inclusion
- Women and men ≥18 and ≤65 years of age
- Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates)
- Routinely treated and monitored for MS
- Speak and read Danish
- Deemed physically and mentally able to participate in this study
Exclusion
- Active malignancy
- Diagnosis of Crohn's disease and ulcerative colitis
- Other comorbidities deemed to be relevant
- Haematopoietic stem cell transplantation
- Current or past treatment with non-MS related treatments deemed to be relevant
- Pregnancy or lactation